Page last updated: 2024-12-06

posatirelin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

posatirelin: stimulates oxygen consumption [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71230
CHEMBL ID2105243
CHEBI ID135486
SCHEMBL ID195247
MeSH IDM0156099

Synonyms (32)

Synonym
rgh-2202
paad-leu-pro-nh2
pyladox
posatirelin
posatirelinum [inn-latin]
(-)-(2s)-n-(1s)-1-((2s)-2-carbamoyl-1-pyrrolidinyl)carbonyl-3-(methylbutyl)-6-oxopipecolamide
posatirelina [inn-spanish]
l-pyro-2-aminoadipyl-l-leucyl-l-prolinamide
brn 6006446
(2s)-n((1s)-1-(((2s)-2-carbamoyl-1-pyrrolidinyl)carbonyl)-3-methylbutyl)-6-oxopipecolamide
posatireline [inn-french]
l-6-ketopiperidine-2-carbonyl-leucyl-l-prolin-amide
posatirelin [inn]
(s)-l-leucyl-n-((6-oxo-2-piperidinyl)carbonyl)-l-prolinamide
l-prolinamide, n-((6-oxo-2-piperidinyl)carbonyl)-l-leucyl-, (s)-
(2s)-n-[(2s)-1-[(2s)-2-carbamoylpyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]-6-oxopiperidine-2-carboxamide
78664-73-0
posatireline
CHEMBL2105243
78u6302arl ,
posatirelinum
unii-78u6302arl
posatirelina
posatirelin [mi]
posatirelin [jan]
posatirelin [mart.]
SCHEMBL195247
CHEBI:135486
(s)-n-((s)-1-((s)-2-carbamoylpyrrolidin-1-yl)-4-methyl-1-oxopentan-2-yl)-6-oxopiperidine-2-carboxamide
Q27266691
DTXSID301318172
AKOS040753598

Research Excerpts

Treatment

Treatment with posatirelin was without effect on the number of nerve cell profiles or of GFAP-immunoreactive astrocytes both at 4 and 8 weeks after LC lesioning.

ExcerptReferenceRelevance
"Treatment with posatirelin was without effect on the number of nerve cell profiles or of GFAP-immunoreactive astrocytes both at 4 and 8 weeks after NBM lesioning."( Effect of the thyrotropin releasing hormone analogue posatirelin (RGH 2202) on microanatomical changes induced by lesions of the nucleus basalis magnocellularis in the rat.
Amenta, F; Coppi, G; Maggioni, A; Olgiati, V; Panocka, I; Sabbatini, M, 1997
)
0.89
"Treatment with posatirelin was without effect on the number of nerve cell and of GFAP-immunoreactive astrocyte profiles at both 4 and 8 weeks after LC lesioning, with the exception of nerve cells of the frontal cortex in monolaterally-lesioned rats which were increased 8 weeks after lesioning."( Effect of treatment with the neuroactive peptide posatirelin on microanatomical changes of frontal cortex and hippocampus caused by lesions of the locus coeruleus.
Amenta, F; Coppi, G; Maggioni, A; Olgiati, V; Panocka, I; Sabbatini, M, 1997
)
0.89

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters were estimated using a model-independent approach."( Pharmacokinetic profile and endocrine effects of posatirelin treatment in healthy elderly subjects.
Ambrosoli, L; Cherubini, A; Girardello, R; Lowenthal, DT; Palumbo, B; Parnetti, L; Poli, A; Reboldi, G; Santeusanio, F; Senin, U, 1996
)
0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID119739Reduction of hexobarbital induced sleeping time in mice.1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Synthesis of thyrotropin-releasing hormone analogues. 2. Tripeptides structurally greatly differing from TRH with high central nervous system activity.
AID176950Doses that inhibited cataleptic effect of haloperidol in rat by 50%1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Synthesis of thyrotropin-releasing hormone analogues. 2. Tripeptides structurally greatly differing from TRH with high central nervous system activity.
AID171620Thyrotropin releasing activity (TSH) was evaluated by measuring the TSH response to the compound by radioimmunoassay in two doses in the rat1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Synthesis of thyrotropin-releasing hormone analogues. 2. Tripeptides structurally greatly differing from TRH with high central nervous system activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (21.74)18.7374
1990's14 (60.87)18.2507
2000's4 (17.39)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.05 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]